Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCX9930 versus continued C5 inhibitor therapy in paroxysmal nocturnal hemoglobinuria with inadequate response
NL-OMON51609Phase 2Withdrawn
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vimircopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoints: Change from baseline in hemoglobin, Treatment-emergent adverse events and 4 more. Planned start Jan 2022; status: withdrawn.
02
Drugs
vimircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NL-OMON51609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51609.